Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions, Inc. investor Casdin Capital and affiliates report a 9.7% beneficial ownership stake, or 4,757,165 common shares. This percentage is based on 48,857,415 shares outstanding as of April 30, 2026. The stake is held through Casdin Partners Master Fund, L.P., its general partner, and Eli Casdin.
The shares were acquired for investment using the fund’s working capital, without specific borrowing for this position. The group states it currently has no concrete plans for corporate changes but may engage with management, directors, and other shareholders on alternatives to maximize shareholder value and could adjust its holdings over time.
BioLife Solutions Inc. reported insider activity by Casdin-affiliated entities. Casdin Partners Master Fund, L.P. completed open-market sales totaling 1,200,000 shares of common stock over three days. The fund sold 300,000 shares at $22.65 on May 19, 2026, 250,000 shares at $23.70 on May 20, and 650,000 shares at $23.70 on May 21. After these sales, the Master Fund continued to hold 4,757,165 shares indirectly. According to the footnote, these securities are owned directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin.
Casdin Partners Master Fund, L.P. submitted a Form 144 notice regarding proposed sales of Common Stock of BLFS. The filing lists 650,000 shares tied to a broker arrangement and records recent dispositions of 300,000 shares on 05/19/2026 and 250,000 shares on 05/20/2026.
BioLifesolutions, Inc. notice of proposed sale of 250,000 shares of Common Stock under a Form 144 by an affiliate. The filing shows the shares were purchased from the issuer on 08/13/2018 and lists a prior sale of 300,000 shares on 05/19/2026 with gross proceeds of $6,795,000.00. The broker identified is BMO Capital Markets and the securities are listed on NASDAQ.
BioLife Solutions submitted a Form 144 notice indicating proposed sale of 300,000 shares of Common Stock. The filing lists an aggregate value of $6,690,000.00 and references 48,857,415 shares outstanding as of 05/19/2026.
The shares were purchased from the issuer on 08/13/2018 for cash; the filing lists BMO Capital Markets as a broker-dealer. The filing is a notice of a planned sale under resale rules.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 6,506,346 shares of Biolife Solutions Inc. common stock, representing 13.5% of the class. The filing is a Schedule 13G/A amendment signed on 05/15/2026 and states voting and dispositive power is sole for all reported shares.
BioLife Solutions reported stronger results for the quarter ended March 31, 2026, as revenue rose to $27.5 million, up $5.4 million or 25% from a year earlier. Growth was driven mainly by higher demand for its CryoStor biopreservation media.
Gross profit increased to $17.5 million, though gross margin slipped to 64% from 67% due to a less favorable product mix and more lower-margin products. Operating expenses rose 14% to $17.5 million, led by higher personnel costs and research and development tied to the PanTHERA acquisition.
The company moved from a net loss of $0.4 million to net income of $1.2 million from continuing operations, or $0.02 per diluted share. BioLife ended the quarter with $111.5 million in cash, cash equivalents, and available-for-sale securities and believes this is sufficient to fund operations for at least the next twelve months.
BioLife Solutions reported strong first quarter 2026 results, led by revenue of $27.5 million, up 25% from Q1 2025. GAAP gross margin was 64%, while GAAP net income from continuing operations rose to $1.2 million, or $0.02 per diluted share. Adjusted EBITDA reached $6.2 million, representing 22% of revenue.
Cash, cash equivalents, and marketable securities totaled $111.5 million as of March 31, 2026. The company reiterated 2026 guidance for revenue of $112.5–$115.0 million, implying 17–20% growth, with gross margin in the mid‑60% range, GAAP net income for the full year, and continued expansion of adjusted EBITDA margin.
Invesco Ltd. amended its Schedule 13G/A to report beneficial ownership of 2,348,532 shares of BioLife Solutions Inc. The filing states this equals 4.9% of the class, with 2,113,765 shares subject to sole voting power and 2,348,532 shares subject to sole dispositive power.
The amendment is signed by Invesco's Global Head of Compliance and dated 05/06/2026.
BioLife Solutions, Inc. filed Amendment No. 1 to its 2025 annual report to add detailed Part III information on directors, executive officers, governance and compensation instead of filing a proxy. The company reports 2025 revenue of $96.2 million, up from $74.6 million in 2024, and highlights focus on biopreservation media and cell processing tools.
BioLife completed the acquisition of PanTHERA CryoSolutions for about $11.5 million in cash plus $4.5 million in stock and divested SAVSU Technologies, generating about $23.3 million in cash. Named executive officer bonuses were tied to revenue, adjusted EBITDA margin, a clean 2025 annual report with no material weaknesses, and NetSuite MRP implementation, resulting in 2025 payouts at roughly 98% of target.